Perigon Wealth Management increased CRISPR Therapeutics stake by 4.3% in Q4.

Perigon Wealth Management LLC increased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.3% in Q4, owning 14,918 shares worth $934,000. Other institutional investors, including CWM LLC and Tradewinds Capital Management LLC, also expanded their holdings in the company. Needham & Company LLC reiterated a $90 price target on CRISPR Therapeutics, while other research analysts issued bullish reports, with some raising their price targets above $80.